A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/4164 (2006.01)
Patent
CA 2538430
The present invention provides methods of preventing or alleviating sympathetically-enhanced conditions, neurological conditions, ocular conditions and chronic pain without concomitant sedation by peripherally administering to a subject an effective amount of an .alpha.-2A/.alpha.-1A selective agonist, thereby preventing or alleviating the condition or chronic pain without concomitant sedation, where the selective agonist has an .alpha.- 1A efficacy less than that of brimonidine or a ratio of .alpha.-1A/.alpha.-2A potency greater than that of brimonidine.
L'invention concerne des méthodes de prévention ou d'atténuation d'affections médiées par le système nerveux sympathique, d'affections neurologiques, d'affections oculaires et de la douleur chronique sans sédation concomitante, par l'administration périphérique à un patient d'une dose efficace d'un agoniste sélectif .alpha.2A/.alpha.-1A. Ces méthodes préviennent ou atténuent une affection ou la douleur chronique sans sédation concomitante, l'agoniste sélectif ayant une efficacité .alpha.-1A inférieure à celle de la brimonidine ou un rapport de puissance .alpha.1A/.alpha.-2A supérieur à celui de la brimonidine.
Donello John E.
Gil Daniel W.
Allergan Inc.
Gowling Lafleur Henderson Llp
LandOfFree
Novel methods for identifying improved, non-sedating alpha-2... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Novel methods for identifying improved, non-sedating alpha-2..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel methods for identifying improved, non-sedating alpha-2... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2042640